Two new studies in JAMA find that COVID-19 survivors who receive two doses of the Pfizer/BioNTech or Moderna mRNA vaccines may have stronger protection against coronavirus infection, one detailing much lower breakthrough infection rates in previously infected Qataris and one describing higher spike antibody levels among recovered US healthcare workers (HCWs).Breakthrough cases 65% to 82% lower in previously infectedLed by Cornell University researchers in Qatar, the first study involved following 1,531,736 Qataris starting 14 days after receipt of the second dose of Pfizer or Moderna COVID-19 vaccine from Dec 21, 2020, to Sep 19, 2021.The country weathered two COVID-19 surges with the Alpha (B117) and Beta (B1351) variants from January to